XBiotech (STU:4XB) OCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4XB XBiotech Inc STU:4XB
38 GF Score
Price €2.00
GF Value €0.15
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is XBiotech OCF Margin %?

XBiotech STU:4XB 38 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:4XB with a GF Score™ of 38/100 and a GF Value™ of €0.15 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, XBiotech ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. XBiotech's Cash Flow from Operations for the three months ended in Mar. 2026 was €-7.76 Mil. XBiotech's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, XBiotech's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, XBiotech's current OCF Yield % is -60.14%.

The historical rank and industry rank for XBiotech's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of XBiotech was 377.54%. The lowest was -369.68%. And the median was -148.08%.

STU:4XB's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

XBiotech OCF Margin % Related Terms

XBiotech OCF Margin % Historical Data

* Premium members only.

The historical data trend for XBiotech's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech OCF Margin % Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 377.54 -369.72 0.00 0.00 0.00

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:4XB
38GF Score
XBiotech Inc STU:4XB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

XBiotech's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-34.092/0
= %

XBiotech's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-7.758/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
XBiotech (STU:4XB) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on XBiotech and its competitors. According to the industry distribution chart, XBiotech ranks #999999 out of 950 companies in the Biotechnology industry.
Is XBiotech's OCF Margin % too high?
XBiotech's current OCF Margin % is 0.00%. Based on the distribution chart, XBiotech ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XBiotech has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XBiotech's OCF Margin % compare to ACRV and EXOZ?
According to the Biotechnology industry distribution chart, XBiotech ranks #999999 out of 950 companies for OCF Margin %. This places XBiotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on XBiotech and its competitors. XBiotech's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
Based on GuruFocus' analysis, XBiotech (STU:4XB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €2.00 — trading 1233.3% above its estimated fair value. The current OCF Margin % is 0.00%. XBiotech's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For XBiotech (STU:4XB), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is XBiotech (STU:4XB) Overvalued in 2026?

Based on GuruFocus' analysis, XBiotech stock appears to be overvalued. The current stock price of €2.00 is trading 1233.3% above its estimated GF Value™ of €0.15. GuruFocus considers XBiotech to be Significantly Overvalued.

Key valuation signals for STU:4XB:

  • OCF Margin %: 0.00%
  • GF Value™: €0.15 vs. price of €2.00 (1233.3% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:4XB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
38GF Score

Get the complete analysis for STU:4XB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price
€0.15
GF Value